1. Home
  2. MUX vs PVLA Comparison

MUX vs PVLA Comparison

Compare MUX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$18.61

Market Cap

1.1B

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$103.26

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
PVLA
Founded
1979
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MUX
PVLA
Price
$18.61
$103.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
16
Target Price
$21.63
$141.50
AVG Volume (30 Days)
1.2M
290.8K
Earning Date
11-06-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$166,453,000.00
N/A
Revenue This Year
$3.15
N/A
Revenue Next Year
$43.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.38
$11.28
52 Week High
$24.88
$114.69

Technical Indicators

Market Signals
Indicator
MUX
PVLA
Relative Strength Index (RSI) 48.13 56.87
Support Level $19.05 $99.18
Resistance Level $20.22 $114.69
Average True Range (ATR) 1.03 8.47
MACD -0.10 -0.20
Stochastic Oscillator 14.11 64.85

Price Performance

Historical Comparison
MUX
PVLA

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Share on Social Networks: